Shenji Changhua is a biotechnology company concentrating on neurodegenerative disorders including ALS, stroke, Parkinson’s disease, and Alzheimer’s disease. The company is a Tsinghua University technology‑transfer enterprise and its founding team all come from Tsinghua. Its pipeline includes a lead candidate named SNUG01, for which the company plans an IND submission. Recently Shenji Changhua completed a nearly ¥100 million Pre‑A financing to support development. The raised funds will be used primarily for the IND filing of SNUG01 and to advance other pipeline products. The company’s stated goal is to address major unmet medical needs in neurodegenerative diseases.

Total raised

$14M

Funding rounds

1

Latest round

Series A

Latest activity

Aug 2024